2
|
Song KS, Park SC, Sohn DK, Oh JH, Kim MJ, Park JW, Ryoo SB, Jeong SY, Park KJ, Oh HK, Kim DW, Kang SB. Oncologic Risk of Rectal Preservation Against Medical Advice After Chemoradiotherapy for Rectal Cancer: A Multicenter Comparative Cross-Sectional Study with Rectal Preservation as Supported by Surgeon. World J Surg 2020; 43:3216-3223. [PMID: 31410512 DOI: 10.1007/s00268-019-05128-2] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
BACKGROUND Rectal preservation against medical advice after neoadjuvant chemoradiotherapy for rectal cancer may increase oncologic uncertainty. This study aimed to compare the oncologic outcomes of patients undergoing rectal preservation as intended by the surgeon, and the outcomes of patients refusing rectal resection against medical advice. METHODS The study population consisted of patients in whom the rectum was preserved after neoadjuvant chemoradiotherapy for clinical stage I-III mid or low rectal cancer between May 2003 and August 2017 (n = 2883); these patients were divided into those in whom rectal preservation was intended by their surgeon (intended rectal preservation, group A, n = 41) and those in whom the rectum was not resected against medical advice (unintended rectal preservation, group B, n = 101), defined as non-operative management or local excision. RESULTS The tumor distance, age, and performance status of patients were not significantly different between the groups, while the clinical T stage before chemoradiotherapy was lower in group A than in group B (P < 0.001). During the median follow-up period of 34 months (interquartile range 18.0-72.0 months), the 3-year overall survival in group B (59.7%) was worse than that in group A (90.1%; P < 0.001), and 80.2% of group B patients had residual or unknown disease status. CONCLUSIONS This study showed that unintended rectal preservation increases oncologic risk after neoadjuvant chemoradiotherapy for rectal cancer regardless of short-term follow-up. Therefore, these findings could be shared with rectal cancer patients who choose to ignore medical advice after chemoradiotherapy to preserve their rectum.
Collapse
Affiliation(s)
- Kwang-Seop Song
- Center for Colorectal Cancer, Research Institute and Hospital, National Cancer Center, Goyang, Republic of Korea
| | - Sung Chan Park
- Center for Colorectal Cancer, Research Institute and Hospital, National Cancer Center, Goyang, Republic of Korea
| | - Dae Kyung Sohn
- Center for Colorectal Cancer, Research Institute and Hospital, National Cancer Center, Goyang, Republic of Korea
| | - Jae Hwan Oh
- Center for Colorectal Cancer, Research Institute and Hospital, National Cancer Center, Goyang, Republic of Korea
| | - Min Jung Kim
- Department of Surgery, Seoul National University College of Medicine, Seoul National University Hospital, Seoul, Republic of Korea
| | - Ji Won Park
- Department of Surgery, Seoul National University College of Medicine, Seoul National University Hospital, Seoul, Republic of Korea
| | - Seung-Bum Ryoo
- Department of Surgery, Seoul National University College of Medicine, Seoul National University Hospital, Seoul, Republic of Korea
| | - Seung-Yong Jeong
- Department of Surgery, Seoul National University College of Medicine, Seoul National University Hospital, Seoul, Republic of Korea
| | - Kyu Joo Park
- Department of Surgery, Seoul National University College of Medicine, Seoul National University Hospital, Seoul, Republic of Korea
| | - Heung-Kwon Oh
- Department of Surgery, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea
| | - Duck-Woo Kim
- Department of Surgery, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea
| | - Sung-Bum Kang
- Department of Surgery, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea.
| | | |
Collapse
|
4
|
Nougaret S, Vargas HA, Lakhman Y, Sudre R, Do RKG, Bibeau F, Azria D, Assenat E, Molinari N, Pierredon MA, Rouanet P, Guiu B. Intravoxel Incoherent Motion-derived Histogram Metrics for Assessment of Response after Combined Chemotherapy and Radiation Therapy in Rectal Cancer: Initial Experience and Comparison between Single-Section and Volumetric Analyses. Radiology 2016; 280:446-54. [PMID: 26919562 DOI: 10.1148/radiol.2016150702] [Citation(s) in RCA: 141] [Impact Index Per Article: 15.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
Purpose To determine the diagnostic performance of intravoxel incoherent motion (IVIM) parameters and apparent diffusion coefficient (ADC) to assess response to combined chemotherapy and radiation therapy (CRT) in patients with rectal cancer by using histogram analysis derived from whole-tumor volumes and single-section regions of interest (ROIs). Materials and Methods The institutional review board approved this retrospective study of 31 patients with rectal cancer who underwent magnetic resonance (MR) imaging before and after CRT, including diffusion-weighted imaging with 34 b values prior to surgery. Patient consent was not required. ADC, perfusion-related diffusion fraction (f), slow diffusion coefficient (D), and fast diffusion coefficient (D*) were calculated on MR images acquired before and after CRT by using biexponential fitting. ADC and IVIM histogram metrics and median values were obtained by using whole-tumor volume and single-section ROI analyses. All ADC and IVIM parameters obtained before and after CRT were compared with histopathologic findings by using t tests with Holm-Sidak correction. Receiver operating characteristic curves were generated to evaluate the diagnostic performance of IVIM parameters derived from whole-tumor volume and single-section ROIs for prediction of histopathologic response. Results Extreme values aside, results of histogram analysis of ADC and IVIM were equivalent to median values for tumor response assessment (P > .06). Prior to CRT, none of the median ADC and IVIM diffusion metrics correlated with subsequent tumor response (P > .36). Median D and ADC values derived from either whole-volume or single-section analysis increased significantly after CRT (P ≤ .01) and were significantly higher in good versus poor responders (P ≤ .02). Median IVIM f and D* values did not significantly change after CRT and were not associated with tumor response to CRT (P > .36). Interobserver agreement was excellent for whole-tumor volume analysis (range, 0.91-0.95) but was only moderate for single-section ROI analysis (range, 0.50-0.63). Conclusion Median D and ADC values obtained after CRT were useful for discrimination between good and poor responders. Histogram metrics did not add to the median values for assessment of tumor response. Volumetric analysis demonstrated better interobserver reproducibility when compared with single-section ROI analysis. (©) RSNA, 2016 Online supplemental material is available for this article.
Collapse
Affiliation(s)
- Stephanie Nougaret
- From the Department of Abdominal Imaging, Saint Eloi University Hospital, CHU Montpellier, 80 Avenue Augustin Fliche, 34295 Montpellier Cedex 5, France (S.N., M.A.P., B.G.); Institute of Cancer Research of Montpellier (IRCM-U1194), Montpellier, France (S.N., F.B., D.A., B.G.); INSERM, Unit 896, Montpellier, France (S.N., B.G.); Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY (H.A.V., Y.L., R.K.G.D.); Departments of Radiology (R.S.), Histopathology (F.B.), Oncology and Radiation Therapy (D.A., E.A.), and Surgery (P.R.), Montpellier Cancer Institute, Montpellier, France; and Department of Statistics-IMAG, Montpellier University, CHU Montpellier, Montpellier, France (N.M.)
| | - Hebert Alberto Vargas
- From the Department of Abdominal Imaging, Saint Eloi University Hospital, CHU Montpellier, 80 Avenue Augustin Fliche, 34295 Montpellier Cedex 5, France (S.N., M.A.P., B.G.); Institute of Cancer Research of Montpellier (IRCM-U1194), Montpellier, France (S.N., F.B., D.A., B.G.); INSERM, Unit 896, Montpellier, France (S.N., B.G.); Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY (H.A.V., Y.L., R.K.G.D.); Departments of Radiology (R.S.), Histopathology (F.B.), Oncology and Radiation Therapy (D.A., E.A.), and Surgery (P.R.), Montpellier Cancer Institute, Montpellier, France; and Department of Statistics-IMAG, Montpellier University, CHU Montpellier, Montpellier, France (N.M.)
| | - Yulia Lakhman
- From the Department of Abdominal Imaging, Saint Eloi University Hospital, CHU Montpellier, 80 Avenue Augustin Fliche, 34295 Montpellier Cedex 5, France (S.N., M.A.P., B.G.); Institute of Cancer Research of Montpellier (IRCM-U1194), Montpellier, France (S.N., F.B., D.A., B.G.); INSERM, Unit 896, Montpellier, France (S.N., B.G.); Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY (H.A.V., Y.L., R.K.G.D.); Departments of Radiology (R.S.), Histopathology (F.B.), Oncology and Radiation Therapy (D.A., E.A.), and Surgery (P.R.), Montpellier Cancer Institute, Montpellier, France; and Department of Statistics-IMAG, Montpellier University, CHU Montpellier, Montpellier, France (N.M.)
| | - Romain Sudre
- From the Department of Abdominal Imaging, Saint Eloi University Hospital, CHU Montpellier, 80 Avenue Augustin Fliche, 34295 Montpellier Cedex 5, France (S.N., M.A.P., B.G.); Institute of Cancer Research of Montpellier (IRCM-U1194), Montpellier, France (S.N., F.B., D.A., B.G.); INSERM, Unit 896, Montpellier, France (S.N., B.G.); Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY (H.A.V., Y.L., R.K.G.D.); Departments of Radiology (R.S.), Histopathology (F.B.), Oncology and Radiation Therapy (D.A., E.A.), and Surgery (P.R.), Montpellier Cancer Institute, Montpellier, France; and Department of Statistics-IMAG, Montpellier University, CHU Montpellier, Montpellier, France (N.M.)
| | - Richard K G Do
- From the Department of Abdominal Imaging, Saint Eloi University Hospital, CHU Montpellier, 80 Avenue Augustin Fliche, 34295 Montpellier Cedex 5, France (S.N., M.A.P., B.G.); Institute of Cancer Research of Montpellier (IRCM-U1194), Montpellier, France (S.N., F.B., D.A., B.G.); INSERM, Unit 896, Montpellier, France (S.N., B.G.); Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY (H.A.V., Y.L., R.K.G.D.); Departments of Radiology (R.S.), Histopathology (F.B.), Oncology and Radiation Therapy (D.A., E.A.), and Surgery (P.R.), Montpellier Cancer Institute, Montpellier, France; and Department of Statistics-IMAG, Montpellier University, CHU Montpellier, Montpellier, France (N.M.)
| | - Frederic Bibeau
- From the Department of Abdominal Imaging, Saint Eloi University Hospital, CHU Montpellier, 80 Avenue Augustin Fliche, 34295 Montpellier Cedex 5, France (S.N., M.A.P., B.G.); Institute of Cancer Research of Montpellier (IRCM-U1194), Montpellier, France (S.N., F.B., D.A., B.G.); INSERM, Unit 896, Montpellier, France (S.N., B.G.); Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY (H.A.V., Y.L., R.K.G.D.); Departments of Radiology (R.S.), Histopathology (F.B.), Oncology and Radiation Therapy (D.A., E.A.), and Surgery (P.R.), Montpellier Cancer Institute, Montpellier, France; and Department of Statistics-IMAG, Montpellier University, CHU Montpellier, Montpellier, France (N.M.)
| | - David Azria
- From the Department of Abdominal Imaging, Saint Eloi University Hospital, CHU Montpellier, 80 Avenue Augustin Fliche, 34295 Montpellier Cedex 5, France (S.N., M.A.P., B.G.); Institute of Cancer Research of Montpellier (IRCM-U1194), Montpellier, France (S.N., F.B., D.A., B.G.); INSERM, Unit 896, Montpellier, France (S.N., B.G.); Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY (H.A.V., Y.L., R.K.G.D.); Departments of Radiology (R.S.), Histopathology (F.B.), Oncology and Radiation Therapy (D.A., E.A.), and Surgery (P.R.), Montpellier Cancer Institute, Montpellier, France; and Department of Statistics-IMAG, Montpellier University, CHU Montpellier, Montpellier, France (N.M.)
| | - Eric Assenat
- From the Department of Abdominal Imaging, Saint Eloi University Hospital, CHU Montpellier, 80 Avenue Augustin Fliche, 34295 Montpellier Cedex 5, France (S.N., M.A.P., B.G.); Institute of Cancer Research of Montpellier (IRCM-U1194), Montpellier, France (S.N., F.B., D.A., B.G.); INSERM, Unit 896, Montpellier, France (S.N., B.G.); Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY (H.A.V., Y.L., R.K.G.D.); Departments of Radiology (R.S.), Histopathology (F.B.), Oncology and Radiation Therapy (D.A., E.A.), and Surgery (P.R.), Montpellier Cancer Institute, Montpellier, France; and Department of Statistics-IMAG, Montpellier University, CHU Montpellier, Montpellier, France (N.M.)
| | - Nicolas Molinari
- From the Department of Abdominal Imaging, Saint Eloi University Hospital, CHU Montpellier, 80 Avenue Augustin Fliche, 34295 Montpellier Cedex 5, France (S.N., M.A.P., B.G.); Institute of Cancer Research of Montpellier (IRCM-U1194), Montpellier, France (S.N., F.B., D.A., B.G.); INSERM, Unit 896, Montpellier, France (S.N., B.G.); Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY (H.A.V., Y.L., R.K.G.D.); Departments of Radiology (R.S.), Histopathology (F.B.), Oncology and Radiation Therapy (D.A., E.A.), and Surgery (P.R.), Montpellier Cancer Institute, Montpellier, France; and Department of Statistics-IMAG, Montpellier University, CHU Montpellier, Montpellier, France (N.M.)
| | - Marie-Ange Pierredon
- From the Department of Abdominal Imaging, Saint Eloi University Hospital, CHU Montpellier, 80 Avenue Augustin Fliche, 34295 Montpellier Cedex 5, France (S.N., M.A.P., B.G.); Institute of Cancer Research of Montpellier (IRCM-U1194), Montpellier, France (S.N., F.B., D.A., B.G.); INSERM, Unit 896, Montpellier, France (S.N., B.G.); Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY (H.A.V., Y.L., R.K.G.D.); Departments of Radiology (R.S.), Histopathology (F.B.), Oncology and Radiation Therapy (D.A., E.A.), and Surgery (P.R.), Montpellier Cancer Institute, Montpellier, France; and Department of Statistics-IMAG, Montpellier University, CHU Montpellier, Montpellier, France (N.M.)
| | - Philippe Rouanet
- From the Department of Abdominal Imaging, Saint Eloi University Hospital, CHU Montpellier, 80 Avenue Augustin Fliche, 34295 Montpellier Cedex 5, France (S.N., M.A.P., B.G.); Institute of Cancer Research of Montpellier (IRCM-U1194), Montpellier, France (S.N., F.B., D.A., B.G.); INSERM, Unit 896, Montpellier, France (S.N., B.G.); Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY (H.A.V., Y.L., R.K.G.D.); Departments of Radiology (R.S.), Histopathology (F.B.), Oncology and Radiation Therapy (D.A., E.A.), and Surgery (P.R.), Montpellier Cancer Institute, Montpellier, France; and Department of Statistics-IMAG, Montpellier University, CHU Montpellier, Montpellier, France (N.M.)
| | - Boris Guiu
- From the Department of Abdominal Imaging, Saint Eloi University Hospital, CHU Montpellier, 80 Avenue Augustin Fliche, 34295 Montpellier Cedex 5, France (S.N., M.A.P., B.G.); Institute of Cancer Research of Montpellier (IRCM-U1194), Montpellier, France (S.N., F.B., D.A., B.G.); INSERM, Unit 896, Montpellier, France (S.N., B.G.); Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY (H.A.V., Y.L., R.K.G.D.); Departments of Radiology (R.S.), Histopathology (F.B.), Oncology and Radiation Therapy (D.A., E.A.), and Surgery (P.R.), Montpellier Cancer Institute, Montpellier, France; and Department of Statistics-IMAG, Montpellier University, CHU Montpellier, Montpellier, France (N.M.)
| |
Collapse
|